全文获取类型
收费全文 | 2094篇 |
免费 | 162篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 62篇 |
妇产科学 | 51篇 |
基础医学 | 246篇 |
口腔科学 | 172篇 |
临床医学 | 166篇 |
内科学 | 430篇 |
皮肤病学 | 80篇 |
神经病学 | 137篇 |
特种医学 | 36篇 |
外科学 | 252篇 |
综合类 | 58篇 |
一般理论 | 4篇 |
预防医学 | 200篇 |
眼科学 | 129篇 |
药学 | 126篇 |
中国医学 | 12篇 |
肿瘤学 | 92篇 |
出版年
2023年 | 25篇 |
2022年 | 22篇 |
2021年 | 87篇 |
2020年 | 66篇 |
2019年 | 103篇 |
2018年 | 77篇 |
2017年 | 52篇 |
2016年 | 71篇 |
2015年 | 79篇 |
2014年 | 84篇 |
2013年 | 129篇 |
2012年 | 159篇 |
2011年 | 140篇 |
2010年 | 83篇 |
2009年 | 67篇 |
2008年 | 105篇 |
2007年 | 120篇 |
2006年 | 95篇 |
2005年 | 95篇 |
2004年 | 76篇 |
2003年 | 71篇 |
2002年 | 44篇 |
2001年 | 24篇 |
2000年 | 30篇 |
1999年 | 31篇 |
1998年 | 12篇 |
1997年 | 16篇 |
1995年 | 6篇 |
1992年 | 17篇 |
1991年 | 20篇 |
1990年 | 15篇 |
1989年 | 28篇 |
1988年 | 18篇 |
1987年 | 15篇 |
1986年 | 10篇 |
1985年 | 16篇 |
1984年 | 7篇 |
1983年 | 8篇 |
1981年 | 8篇 |
1979年 | 13篇 |
1977年 | 5篇 |
1975年 | 6篇 |
1974年 | 9篇 |
1973年 | 6篇 |
1972年 | 9篇 |
1971年 | 12篇 |
1969年 | 15篇 |
1968年 | 8篇 |
1967年 | 7篇 |
1966年 | 7篇 |
排序方式: 共有2265条查询结果,搜索用时 15 毫秒
1.
2.
Farah Deeba Manyou Ma Mehran Pesteie Jefferson Terry Denise Pugash Jennifer A. Hutcheon Chantal Mayer Septimiu Salcudean Robert Rohling 《Ultrasound in medicine & biology》2019,45(5):1081-1093
Attenuation coefficient estimation has the potential to be a useful tool for placental tissue characterization. A current challenge is the presence of inhomogeneities in biological tissue that result in a large variance in the attenuation coefficient estimate (ACE), restricting its clinical utility. In this work, we propose a new Attenuation Estimation Region Of Interest (AEROI) selection method for computing the ACE based on the (i) envelope signal-to-noise ratio deviation and (ii) coefficient of variation of the transmit pulse bandwidth. The method was first validated on a tissue-mimicking phantom, for which an 18%–21% reduction in the standard deviation of ACE and a 14%–24% reduction in the ACE error, expressed as a percentage of reported ACE, were obtained. A study on 59 post-delivery clinically normal placentas was then performed. The proposed AEROI selection method reduced the intra-subject standard deviation of ACE from 0.72 to 0.39 dB/cm/MHz. The measured ACE of 59 placentas was 0.77 ± 0.37 dB/cm/MHz, which establishes a baseline for future studies on placental tissue characterization. 相似文献
3.
4.
5.
6.
7.
Javed A. Shaik Nima Estharabadi Ronda S. Farah Maria K. Hordinsky 《Experimental dermatology》2020,29(10):1004-1011
Platelet α-granules release growth factors (GFs) that promote healing and tissue regeneration. Platelet-rich plasma (PRP) is shown to be beneficial in treating alopecia, and however, clinical response can be inconsistent. Due to several fold enrichment of platelets secreting large quantities of GFs following PRP injections, heterogeneity in amounts of GFs secreted by platelets may contribute to inconsistent clinical responses. Herein, we evaluated factors that could potentially contribute to heterogeneous secretion of GFs by platelets. We measured platelet secretion of transforming growth factor beta1 (TGFβ1), platelet-derived growth factor (PDGF-BB), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF2) in aliquots of de-identified PRP samples from female patients undergoing therapy in the hair disease clinic. Although secretion of GFs by platelets was comparable in PRP samples of patients with non-cicatricial and cicatricial alopecia, a Shapiro-Wilk test for normal distribution indicated significant variability across all patient samples. The amount of GF secreted by platelets was comparable when PRP prepared from two FDA-cleared devices with distinct techniques were compared. We provide evidence of platelets secreting heterogeneous amounts of GFs within each sample as high and low secretion of random factors could be simultaneously detected. These results suggest inherent heterogeneity in secretion of GFs by platelets in patient samples that are not influenced by the device used to prepare PRP. Since some GFs could have antagonistic effects on hair growth, a balance between amounts of growth promoting and inhibiting factors may be crucial in determining clinical response to PRP therapy. 相似文献
8.
9.
Emmanuel S. Antonarakis Farah Shaukat Pedro Isaacsson Velho Harsimar Kaur Eugene Shenderov Drew M. Pardoll Tamara L. Lotan 《European urology》2019,75(3):378-382
Mismatch repair (MMR) gene mutations are rare in prostate cancer, and their histological and clinical characteristics are largely unknown. We conducted a retrospective study to explore disease characteristics and treatment outcomes of men with metastatic prostate cancer harboring germline and/or somatic MMR mutations detected using clinical-grade genomic assays. Thirteen patients with a deleterious MMR gene mutation were identified. Median age was 64 yr, 75% had grade group 5 (Gleason sum 9 or 10), 23% had intraductal histology, 46% had metastatic disease at initial diagnosis, and 31% had visceral metastases. Most patients (46%) had MSH6 mutations, 73% demonstrated microsatellite instability, and median tumor mutational load was 18/Mb (range, 3–165 mutations/Mb). Surprisingly, responses to standard hormonal therapies were very durable (median progression-free survival [PFS] of 67 mo to initial androgen deprivation and median PFS of 26 mo to abiraterone/enzalutamide). Two of four men receiving PD-1 inhibitors achieved a ≥50% prostate-specific antigen response at 12 wk, with a median PFS duration in these four men of 9 mo. Despite aggressive clinical and pathological features, patients with MMR-mutated advanced prostate cancer appear to have particular sensitivity to hormonal therapies, as well as anecdotal responses to PD-1 inhibitors. Certain histological features (grade group 5, intraductal carcinoma) should prompt evaluation for MMR deficiency. These data are only hypothesis generating.
Patient summary
Prostate cancers with mismatch repair gene mutations have aggressive clinical and pathological features; however, these are very sensitive to standard and novel hormonal therapies, and also demonstrate anecdotal sensitivity to PD-1 inhibitors such as pembrolizumab. 相似文献10.
Farah Ladak Jerry T. Dang Noah J. Switzer Valentin Mocanu Daniel W. Birch Shahzeer Karmali 《Surgery for obesity and related diseases》2019,15(3):431-440
BackgroundComplications arising from laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) are not insignificant and can necessitate additional invasive interventions or reoperations.ObjectivesIn this study, we identify early complications that result in nonoperative and operative interventions after LSG and LRYGB, the timeframe within which to expect them, and factors that influence the likelihood of their occurrence.SettingMulti-institutional database from across North America.MethodsData for this study were obtained from Metabolic and Bariatric Accreditation and Quality Improvement Program participant use files for 2015 and 2016. Statistical analysis was performed using STATA 15. Univariate analysis using Χ2 for categoric data and independent t test for continuous data was performed to determine between group differences. Multivariable logistic regression analysis was used to identify predictors of operative and nonoperative reinterventions.ResultsIn 2015 and 2016, 243,747 underwent LRYGB or LSG, of which 3013 (1.24%) required a second operative procedure and 1536 (0.63%) required an invasive but nonoperative intervention. Complications occurred in 5.48% of LRYGB patients and 2.28% of LSG patients, the most common of which was bleeding. LSG was associated with far fewer nonoperative and operative interventions (.85% versus 2.2%, respectively) than LRYGB (.67% versus 2.5%). Renal insufficiency, including dialysis dependency, was an important predictor of reoperations among bariatric surgery patients. This was also true of nonoperative interventions; however, history of pulmonary embolism, and use of therapeutic anticoagulation were marginally stronger predictors.ConclusionsIn a representative, multinational sample, operative and nonoperative interventions were half as likely among LSG patients compared with LRYGB; however, overall rates still remained low. These findings, in conjunction with new efficacy data demonstrating comparable long-term weight loss between LRYGB and LSG, provide further support for the safety, effectiveness, and cost efficiency of LSG. 相似文献